Androgen receptors in prostate cancer

Endocrine-Related Cancer

Volumn 9, Issue 3, 2002, Pages 155-170

  Culig, Z ^a   Klocker, H ^a   Bartsch, G ^a   Hobisch, A ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTISENSE OLIGONUCLEOTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUFENAMIC ACID; GROWTH FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; POLYUNSATURATED FATTY ACID; PROTEIN P27; QUERCETIN; RESVERATROL; STEROID HORMONE; TRANSCRIPTION FACTOR;

ANDROGEN BLOOD LEVEL; APOPTOSIS; CANCER GROWTH; CELL CYCLE; GENE AMPLIFICATION; GENE MUTATION; HORMONAL THERAPY; HUMAN; METASTASIS; PALLIATIVE THERAPY; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; TUMOR CELL;

ANDROGEN ANTAGONISTS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTOR CROSS-TALK; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 0036749684     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0090155     Document Type: Review

References (165)

1. Abreu-Martin MT, Chari A, Palladino AA, Craft NA & Sawyers CL 1999 Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Molecular and Cellular Biology 19 5143-5154.
2. Adler HI, McCurdy MA, Kattan MW, Timme TL, Scardino PT & Thompson TC 1999 Elevated levels of circulating interleukin-6 and transforming growth factor-1 in patients with metastatic prostatic carcinoma. Journal of Urology 161 182-187.
3. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW & Scher HI 1999 Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. Journal of the National Cancer Institute 91 1869-1876.
4. Akakura K, Akimoto S, Ohki T & Shimazaki J 1995 Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology 45 700-704.
5. Alen P, Claessens F, Schoenemakers E, Swinnen JV, Verhoeven G, Rombauts W & Peeters B 1999 Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1 alpha with multiple steroid receptors and identification of an internally deleted ELE1beta isoform. Molecular Endocrinology 13 117-128.
6. Andriani F, Nan B, Yu J, Li X, Weigel NL, McPhaul MJ, Kasper S, Kagawa S, Fang B, Matusik RJ, Denner L & Marcelli M 2001 Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. Journal of the National Cancer Institute 93 1314-1324.
7. Belanger A, Giasson M, Couture J, Dupont A, Cusan L & Labrie F 1988 Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. Prostate 12 79-84.
8. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC & Isaacs JT 1995 Implication of cell kinetic changes during the progression of human prostatic cancer. Clinical Cancer Research 1 473-480.
9. Bevan CL, Hoare S, Claessens F, Heery DM & Parker MG 1999 The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Molecular and Cellular Biology 19 8383-8392.
10. Bonaccorsi L, Carloni V, Muratori M, Salvadori A, Giannini A, Carini M, Serio M, Forti G & Baldi E 2000 Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology 141 3172-3182.
11. Chang CS, Kokontis J & Liao S 1988 Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. PNAS 86 9534-9538.
12. Chen T, Wang LH & Farrar WL 2000 Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Research 60 2132-2135.
13. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB & Jensen RH 1996 Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Research 56 3091-3102.
14. Chung BH, Mitchell SH, Zhang JS & Young CY 2001 Effects of docosahexonic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis 22 1201-1206.
15. Chung TD, Yu JJ, Spiotto MT, Bartkowski M & Simons JW 1999 Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38 199-207.
16. Chung TD, Yu JJ, Kong TA, Spiotto MT & Lin JM 2000 Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 42 1-7.
17. Cleutjens CB, Steketee K, van Eekelen CC, van der Korput JA, Brinkmann AO & Trapman J 1997 Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology 138 5293-5300.
18. Connolly JM & Rose DP 1994 Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 24 167-175.
19. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague JF & Scher HI 1998 Distinct altered patterns of p27kip1 gene expression in benign prostate hyperplasia and prostate carcinoma. Journal of the National Cancer Institute 90 1284-1291.
20. Craft N, Shostak Y, Carey M & Sawyers CL 1999 A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine 5 280-285.
21. Culig Z, Klocker H, Eberle J, Kaspar F, Hobisch A, Cronauer MV & Bartsch G 1993a DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 22 11-22.
22. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G & Klocker H 1993b Mutant androgen receptor detected in an advanced stage of prostatic carcinoma is activated by adrenal androgens and progesterone. Molecular Endocrinology 7 1541-1550.
23. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G & Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Research 54 5474-5478.
24. Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Zhang J, Bartsch G & Klocker H 1997 Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate 32 106-114.
25. Culig Z, Hobisch A, Herold M, Hittmair A, Thurnher M, Eder IE, Cronauer MV, Rieser C, Ramoner R, Bartsch G, Klocker H & Konwalinka G 1998 Interleukin-1β mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. British Journal of Cancer 78 1004-1011.
26. Culig Z, Hoffmann J, Erdel M, Eder I, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K & Klocker H 1999 Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. British Journal of Cancer 81 242-251.
27. Darne C, Veyssiere G & Jean C 1998 Phorbol ester causes ligand-independent activation of the androgen receptor. European Journal of Biochemistry 256 541-549.
28. Dawson NA & McLeod DG 1995 Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. Journal of Urology 153 1946-1947.
29. Degeorges A, Tatoud R, Fauvel Lafeve F, Podgorniak MP, Millot G, de Cremoux P & Calvo F 1996 Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. International Journal of Cancer 68 207-214.
30. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G & Klocker H 2000 Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Therapy 7 997-1007.
31. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IMJ, Bueschen AJ & Love BA 1998 Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New England Journal of Medicine 339 1036-1042.
32. Elo JP, Kvist L & Leinone K 1995 Mutated human androgen receptor gene detected in a prostate cancer patient is also activated by estradiol. Journal of Clinical Endocrinology and Metabolism 80 3494-3500.
33. Evans BAJ, Harper ME, Daniells CE, Watts CE, Matenhelia S, Green J & Griffiths K 1996 Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Prostate 28 162-171.
34. Gao M, Ossowski L & Ferrari AC 1999a Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. Journal of Cellular Physiology 179 336-346.
35. Gao T, Brantley K, Bolu E & McPhaul MJ 1999b RFG (ARA70, ELE1) interacts with the human androgen receptor in a ligand-dependent fashion, but functions only weakly as a coactivator in cotransfection assays. Molecular Endocrinology 13 1645-1656.
36. Giri D, Ozen M & Ittmann M 2001 Interleukin-6 is an autocrine growth factor in human prostate cancer. American Journal of Pathology 159 159-165.
37. Gleave ME, Hsieh JT, Gao CA, von Eschenbach AC & Chung LW 1991 Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Research 51 3753-3761.
38. Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE & Robson CE 2001 Expression of RAC3, a steroid hormone receptor co-activator in prostate cancer. British Journal of Cancer 85 1928-1936.
39. Gomella LG, Ismail M & Nathan FE 1997 Antiandrogen withdrawal syndrome with nilutamide. Journal of Urology 157 1366.
40. Gorelic LS, Lamm DL, Ramzy I, Radwin HM & Shain SA 1987 Androgen receptors in biopsy specimens of prostate adenocarcinoma. Heterogeneity of distribution and relation to prosgnostic significance of receptor measurements for survival of advanced cancer patients. Cancer 60 211-219.
41. Gregory CW, Johnson RTJ, Presnell SC, Mohler JL & French FC 2001a Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft. Journal of Andrology 22 537-548.
42. Gregory CW, Johnson RTJ, Mohler JL, French FS & Wilson EM 2001b Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Research 61 2892-2898.
43. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS & Wilson EM 2001c A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Research 61 4315-4319.
44. Gross M, Liu B, Tan J, French FS, Carey M & Shuai K 2001 Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 20 3880-3887.
45. Guo Y & Kyprianou N 1998 Overexpression of transforming growth factor-betaI receptor type II restores transforming growth factor-betaI sensitivity and signaling in human prostate cancer cells. Cell Growth and Differentiation 9 185-193.
46. Guo Y, Sklar N, Borkowski A & Kyprianou N 1997 Loss of the cyclin-dependent kinase inhibitor p27 (kip1) protein in human prostate cancer correlates with tumor grade. Clinical Cancer Research 3 2269-2274.
47. Gupta C 1999 Modulation of androgen receptor (AR)-mediated transcriptional activity by EGF in the developing mouse reproductive tract primary cells. Molecular and Cellular Endocrinology 152 169-178.
48. Haapala K, Hyytinen ER, Roiha M, Laurila M, Rantala I, Helin HJ & Koivisto PA 2001 Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Laboratory Investigations 81 1647-1651.
49. Han G, Foster BA, Mistry S, Buchanan G, Harris JM, Tilley WD & Greenberg NM 2001 Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in authochthonous prostate cancer. Journal of Biological Chemistry 276 11204-11213.
50. Harada S, Keller ET, Fujimoto N, Koshida K, Namiki M, Matsumoto T & Mizokami A 2001 Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Prostate 46 319-326.
51. Harris SE, Rong Z, Harris MA & Lubahn DB 1990 Androgen receptor in human prostate carcinoma LNCaP/Adep cells contains a mutation which alters the specificity of the steroid-dependent transcriptional activation region. Proceedings of the 72nd Annual Meeting of the Endocrine Society, Atlanta, GA, p93.
52. Hayes SA, Zarnegar M, Sharma M, Yang F, Peehl DM, ten Dijke P & Sun Z 2001 SMAD3 represses androgen receptor-mediated transcription. Cancer Research 61 2112-2118.
53. He B, Kemppainen JA, Voegel JJ, Gronemeyer H & Wilson EM 1999 Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. Journal of Biological Chemistry 274 37219-37225.
54. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP & Brown TJ 1997 Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Molecular and Cellular Endocrinology 126 59-73.
55. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H & Hittmair A 1995 Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Research 55 3068-3072.
56. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H & Hittmair A 1996 Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28 129-135.
57. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H & Culig Z 1998 Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Research 58 4640-4645.
58. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch GJ, Klocker H, Bartsch G & Culig Z 2000 Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. Journal of Pathology 191 239-244.
59. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H & Culig Z 2001 Prostate cancer cells (LNCaP) generated after long-term interleukin-6 treatment express interleukin-6 and acquire an interleukin-6-partially resistant phenotype. Clinical Cancer Research 7 2941-2948.
60. Hofman K, Swinnen JV, Claessens F, Verhoeven G & Heyns W 2000 Apparent coactivation due to interference of expression constructs with nuclear receptor expression. Molecular and Cellular Endocrinology 168 21-29.
61. Hofman K, Swinnen JV, Verhoeven G & Heyns W 2001 E2F activity is biphasically regulated by androgens in LNCaP cells. Biochemical and Biophysical Research Communications 283 97-101.
62. Hsieh TC, Xu W & Chiao JW 1995 Growth regulation and cellular changes during differentiation of human prostatic cancer LNCaP cells as induced by T lymphocyte-conditioned medium. Experimental Cell Research 218 137-143.
63. Huggins C & Hodges CV 1941 Studies on prostatic cancer: the effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293-297.
64. Ikonen T, Palvimo JJ & Jänne OA 1997 Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. Journal of Biological Chemistry 272 29821-29828.
65. Isaacs JT, Isaacs WB, Feitz WFJ & Scheres J 1986 Establishment and localization of seven Dunning rat prostatic cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9 261-281.
66. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB & Nassif N 1998 Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Research 58 5310-5314.
67. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J & Brinkmann AO 1991 Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Molecular Endocrinology 5 1396-1404.
68. Joseph IB, Nelson JB, Denmeade SR & Isaacs JT 1997 Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clinical Cancer Research 3 2507-2511.
69. Junicho A, Matsuda T, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H & Muraguchi A 2000 Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochemical and Biophysical Research Communications 278 9-13.
70. Kallio PJ, Jänne OA & Palvimo JJ 1994 Agonists, but not antagonists, alter the conformation of the hormone-binding domain of androgen receptor. Endocrinology 134 998-1001.
71. Kang HY, Lin HK, Hu YC, Yeh S, Huang KE & Chang C 2001 From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. PNAS 98 3018-3023.
72. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR & Wilson EM 1999 Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Molecular Endocrinology 13 440-454.
73. Kim IY, Kim JH, Zelner DJ, Ahn HJ, Sensibar JA & Lee C 1996 Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology 137 991-999.
74. Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, Reznikoff CR, Bova GS, Friedl A & Jarrard DF 2000 Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Research 60 3623-3630.
75. Knudsen KE, Cavenee WK & Arden KC 1999 D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Research 59 2297-2301.
76. Kokontis J, Takakura K, Hay N & Liao S 1994 Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Research 54 1566-1573.
77. Kokontis JM, Hay N & Liao S 1998 Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Molecular Endocrinology 12 941-953.
78. Langley E, Kemppainen JA & Wilson EM 1998 Intracellular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. Journal of Biological Chemistry 273 92-101.
79. Laufer M, Sinibaldi VJ, Carducci MA & Eisenberger MA 1999 Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer. Urology 54 745.
80. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS & Kozlowski JM 1995 Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136 796-805.
81. Lee DK, Duan HO & Chang C 2000 From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator. Journal of Biological Chemistry 275 9308-9313.
82. Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Holland JF & Kirschenbaum A 1998 Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 139 4672-4679.
83. Li P, Nicosia SV & Bai W 2001 Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. Journal of Biological Chemistry 276 20444-20450.
84. Lin D-L, Whitney MC, Yao Z & Keller ET 2001a Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor. Clinical Cancer Research 7 1773-1781.
85. Lin HK, Yeh S, Kang HY & Chang C 2001b Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. PNAS 98 7200-7205.
86. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL & Visakorpi T 2001 Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research 61 3550-3555.
87. Lu ML, Schneider MC, Zheng Y, Zhang X & Richie JP 2001 Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. Journal of Biological Chemistry 276 13442-13451.
88. Lu S, Tsai SY & Tsai MJ 1997 Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Research 57 4511-4516.
89. Lu W, Luo Y, Kan M & McKeehan WL 1999 Fibroblast growth factor-10. A second candidate to stromal to epithelial cell andromedin in prostate. Journal of Biological Chemistry 274 12827-12834.
90. McDonald S, Brive L, Agus DB, Scher HI & Ely KR 2000 Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Research 60 2317-2322.
91. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL & Lamb DJ 2000 Androgen receptor mutations in prostate cancer. Cancer Research 60 944-949.
92. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Maredo S, Otto N, Joschko S, Scholz P, Wegg A, Basler S, Schafer M, Egner U & Carrondo MA 2000 Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. Journal of Biological Chemistry 275 26164-26171.
93. Matsuda T, Junicho A, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H & Muraguchi A 2001 Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochemical and Biophysical Research Communications 283 179-187.
94. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C & Auricchio F 2000 Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO Journal 19 5406-5417.
95. Mitchell SH, Zhu W & Young CY 1999 Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Research 59 5892-5899.
96. Miyake H, Tolcher A & Gleave ME 2000a Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligonucleotides. Journal of the National Cancer Institute 92 34-41.
97. Miyake H, Chi KN & Gleave ME 2000b Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clinical Cancer Research 6 1655-1663.
98. Miyamoto H, Yeh S, Wilding G & Chang C 1998 Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. PNAS 95 7379-7384.
99. Mononen N, Syrjakoski K, Matikainen M, Tammela TL, Schleutker J, Kallioniemi OP, Trapman J & Koivisto PA 2000 Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. Cancer Research 60 6479-6481.
100. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF & Tindall DJ 1992 Hormonal regulation of prostate-specific antigen (PSA) in the human adenocarcinoma cell line, LNCaP. Prostate 21 63-73.
101. Nakhla AM, Romas NA & Rosner W 1997 Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone-binding globulin. Journal of Biological Chemistry 272 6838-6841.
102. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J & Thompson TC 1998 Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nature Medicine 4 1062-1064.
103. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC & Logothetis CJ 1997 Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clinical Cancer Research 3 2493-2500.
104. Nazareth LV & Weigel NL 1996 Activation of the human androgen receptor through a protein kinase A signaling pathway. Journal of Biological Chemistry 271 19900-19907.
105. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL & Pollak M 2001 In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor-I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Research 61 6276-6280.
106. Nieh PT 1995 Withdrawal phenomenon with the antiandrogen casodex. Journal of Urology 153 1070-1072.
107. Okamoto M, Lee C & Oyasu R 1997a Autocrine effect of androgen on proliferation of an androgen-responsive prostatic carcinoma cell line, LNCaP: role of interleukin-6. Endocrinology 138 5071-5074.
108. Okamoto M, Lee C & Oyasu R 1997b Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Research 57 141-146.
109. Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, Bartsch G, Klocker H & Cato AC 1995 Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. International Journal of Cancer 63 544-550.
110. Quarmby VE, Beckman WCJ, Cooke DB, Lubahn DB, Joseph DR, Wilson EM & French FS 1990 Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Research 50 735-739.
111. Reinikainen P, Palvimo JJ & Janne OA 1996 Effects of mitogens on androgen receptor-mediated transactivation. Endocrinology 137 4351-4357.
112. Sadar MD & Gleave ME 2000 Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Research 60 5825-5831.
113. Sadi MV, Walsh PC & Barrack ER 1991 Immunohistochemical study of androgen receptors in metastatic prostate cancer - comparison of receptor content and response to hormonal therapy. Cancer 67 3057-3064.
114. Scher HI & Kelly WK 1993 Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. Journal of Clinical Oncology 11 1566-1572.
115. Schmid HP, Adolfsson J & Aus G 2001 Active monitoring (deferred treatment or watchful waiting) in the treatment of prostate cancer. A review. European Urology 40 488-494.
116. Schoenmakers E, Verrijdkt G, Peeters B, Verhoeven G, Rombauts W & Claessens F 2000 Differences in DNA binding characteristics of the androgen and glucocorticoid receptors can determine hormone-specific responses. Journal of Biological Chemistry 275 12290-12297.
117. Schuurmans ALG, Bolt J, Voorhorst M, Blankenstein RA & Mulder E 1988 Regulation of growth and epidermal growth factor receptor levels of LNCaP prostatic tumor cells by different steroids. International Journal of Cancer 42 917-922.
118. Sella A, Flex D, Sulkes A & Baniel J 1998 Antiandrogen withdrawal syndrome with cyproterone acetate. Urology 52 1091-1093.
119. Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, Bumstein KL & Nanus DM 2000 Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 141 1699-1704.
120. Small EJ & Carroll PR 1994 Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43 408-410.
121. Sprenger CC, Vail ME, Evans K, Simurdak J & Plymate SR 2002 Overexpression of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene 21 140-147.
122. Stanbrough M, Leav I, Kwan PW, Bubley GJ & Balk SP 2001 Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. PNAS 98 10823-10828.
123. Steiner M 1995 Transforming growth factor-beta and prostate cancer. World Journal of Urology 13 329-336.
124. Sun Z, Pan J, Hope WX, Cohen SN & Balk SP 1999 Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. Cancer 86 689-696.
125. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVereWhite RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL & French FS 1997 Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Molecular Endorinology 11 450-459.
126. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN & Balk SP 1995 Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. New England Journal of Medicine 332 1393-1398.
127. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B & Balk SP 1999 Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Research 59 2511-2515.
128. Tekur S, Lau KM, Long J, Burnstein K & Ho SM 2001 Expression of RFG/ELE1alpha/ARA70 in normal and malignant prostatic epithelial cell cultures and lines: regulation by methylation and sex steroids. Molecular Carcinogenesis 30 1-13.
129. Thompson J, Saatcioglu F, Janne OA & Palvimo JJ 2001 Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity. Molecular Endocrinology 6 923-935.
130. Tilley WD, Marcelli M, Wilson JD & McPhaul MJ 1989 Characterization and expression of a cDNA encoding the human androgen receptor. PNAS 86 327-331.
131. Tilley WD, Wilson CM, Marcelli M & McPhaul MJ 1990 Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Research 50 5382-5386.
132. Trapman J, Klaassen P, Kuiper GG, van der Korput JA, Faber PW, van Rooij HC, Geurts van Kessel A, Voorhorst MM & Mulder E 1988 Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochemical and Biophysical Research Communications 153 241-248.
133. Truica CI, Byers S & Gelmann EP 2000 Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Research 60 4709-4713.
134. Twillie DA, Eisenberger MA, Carducci MA, Hseih W-S, Kim WY & Simons JW 1995 Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45 542-549.
135. Van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CCJ, Mulder E, Boersma W & Trapman J 1991 Androgen receptors in endocrine-therapy-resistant human prostate cancer. International Journal of Cancer 48 189-193.
136. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J & Brinkmann AO 1990a A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochemical and Biophysical Research Communications 17 534-540.
137. Veldscholte J, Voorhost-Ogink MM, Bolt-de Vries J, van Rooij HC, Trapman J & Mulder E 1990b Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochimica et Biophysica Acta 1052 187-194.
138. Veldscholte J, Berrevoets CA, Zegers ND, van der Kwast TH, Grootgoed JA & Mulder E 1992 Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry 31 7422-7430.
139. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J & Kallioniemi OP 1995 In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 9 401-406.
140. Vlietstra RJ, van Alerwijk DC, Hermans KG, van Steenbrugge GJ & Trapman J 1998 Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Research 58 2720-2723.
141. Wang LG, Liu XM, Kreis W & Budman DR 1999 Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Biochemical and Biophysical Research Communications 259 21-28.
142. Wang LG, Ossowski L & Ferrari AC 2001a Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Research 61 7544-7551.
143. Wang X, Yeh S, Wu G, Hsu CL, Wang L, Chiang T, Yang Y, Guo Y & Chang C 2001b Identification and characterization of a novel androgen receptor coregulator ARA267.alpha in prostate cancer cells. Journal of Biological Chemistry 276 40417-40423.
144. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH & Hung MC 2000 HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Research 60 6841-6845.
145. Wong CI, Zhou ZX, Sar M & Wilson EM 1993 Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid binding domains. Journal of Biological Chemistry 268 19004-19012.
146. Wong CI, Kelce WR, Sar M & Wilson EM 1995 Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. Journal of Biological Chemistry 270 19998-20003.
147. Wurtz JM, Bourget W, Renaud JP, Vivat V, Chambon P, Moras D & Gronemeyer H 1996 A canonical structure for the ligand-binding domain of nuclear receptors. Nature Structural Biology 3 87-94.
148. Xing N, Chen Y, Mitchell SH & Young CY 2001 Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 22 409-414.
149. Yamamoto A, Hashimoto Y, Kohri K, Ogata E, Kato S, Ikeda K & Nakanishi M 2000 Cyclin E as a coactivator of the androgen receptor. Journal of Cell Biology 150 873-880.
150. Yan G, Fukabori Y, Nikolaropoulos S, Wang F & McKeehan WL 1992 Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Molecular Endocrinology 6 2123-2128.
151. Yang F, Li X, Sharma M, Zamegar M, Lim B & Sun Z 2001 Androgen receptor specifically interacts with a novel p21-activated kinase, PAK6. Journal of Biological Chemistry 276 15345-15353.
152. Ye D, Mendelsohn J & Fan Z 1999 Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clinical Cancer Research 5 2171-2177.
153. Ye J, Wang S, Barger M, Castranova V & Shi X 2000 Activation of androgen response element by cadmium: a potential mechanism for a carcinogenic effect of cadmium in the prostate. Journal of Environmental Pathology, Toxicology and Oncology 19 275-280.
154. Yeh S & Chang C 1996 Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. PNAS 93 5517-5521.
155. Yeh S, Miyamoto H, Shima H & Chang C 1998 From estrogen to androgen receptors: a new pathway for sex hormones in prostate. PNAS 95 5527-5532.
156. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF & Chang C 1999 From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. PNAS 96 5458-5463.
157. Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY & Chang C 2000 Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. PNAS 97 11256-11261.
158. Young CYF, Montgomery BT, Andrews PE, Qiu SD, Bilhartz DL & Tindall DJ 1991 Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Researh 51 3748-3752.
159. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F & Keating A 1993 Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Research 53 1304-1311.
160. Zhang S, Hsieh ML, Zhu W, Klee GG, Tindall DJ & Young CY 1999 Interactive effects of triiodothyronine and androgens on prostate cell growth and gene expression. Endocrinology 140 1665-1671.
161. Zhao XY, Ly LH, Peehl DM & Feldman D 1997 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138 3290-3298.
162. Zhao XY, Boyle B, Krishman AV, Navone NM, Peehl DM & Feldman D 1999 Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. Journal of Urology 162 2192-2199.
163. Zhao XY, Malloy PJ, Krishman AV, Swami S, Navone NM, Peehl DM & Feldman D 2000 Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nature Medicine 6 703-706.
164. Zhu W, Smith A & Young CY 1999 A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of androgen receptor in LNCaP cells. Endocrinology 140 5451-5454.
165. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ & Bernards R 1998 Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes and Development 12 3488-3498.